 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || RC118 / Rongchang Pharma
Trial completion date, Trial primary completion date, Metastases: A Study of RC118 in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors (clinicaltrials.gov) - Feb 20, 2024
P1/2, N=135, Recruiting, Sponsor: RemeGen Co., Ltd.
Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Sep 2025
- |||| Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, RC118 / Rongchang Pharma
New P1/2 trial, Combination therapy, IO biomarker, Metastases: A Study of RC118 Plus Toripalimab in Patients With Locally Advanced Unresectable or Metastatic Solid Tumors (clinicaltrials.gov) - Sep 14, 2023
P1/2, N=64, Recruiting, Sponsor: RemeGen Co., Ltd.
- || RC118 / Rongchang Pharma
Trial completion, Enrollment change, Trial primary completion date, Metastases: A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours (clinicaltrials.gov) - Jun 22, 2023
P1, N=7, Completed, Sponsor: RemeGen Co., Ltd.
Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Sep 2025 Active, not recruiting --> Completed | N=33 --> 7 | Trial primary completion date: Apr 2023 --> Nov 2022
- || RC118 / Rongchang Pharma
Enrollment closed, Metastases: A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours (clinicaltrials.gov) - Nov 18, 2022
P1, N=33, Active, not recruiting, Sponsor: RemeGen Co., Ltd.
Active, not recruiting --> Completed | N=33 --> 7 | Trial primary completion date: Apr 2023 --> Nov 2022 Recruiting --> Active, not recruiting
- ||| RC118 / Rongchang Pharma
Enrollment open, Metastases: A Study of RC118 in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors (clinicaltrials.gov) - Mar 21, 2022
P1/2, N=135, Recruiting, Sponsor: RemeGen Co., Ltd.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| RC118 / Rongchang Pharma
New P1/2 trial, Metastases: A Study of RC118 in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors (clinicaltrials.gov) - Jan 25, 2022
P1/2, N=135, Not yet recruiting, Sponsor: RemeGen Co., Ltd.
- | RC118 / Rongchang Pharma
Trial completion date, Trial primary completion date, Metastases: A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours (clinicaltrials.gov) - Jan 9, 2022
P1, N=33, Recruiting, Sponsor: RemeGen Co., Ltd.
Not yet recruiting --> Recruiting Trial completion date: Feb 2022 --> May 2023 | Trial primary completion date: Dec 2021 --> Apr 2023
- || RC118 / Rongchang Pharma
Enrollment open, Metastases: A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours (clinicaltrials.gov) - Oct 19, 2021
P1, N=33, Recruiting, Sponsor: RemeGen Co., Ltd.
Trial completion date: Feb 2022 --> May 2023 | Trial primary completion date: Dec 2021 --> Apr 2023 Not yet recruiting --> Recruiting
- || RC118 / Rongchang Pharma
New P1 trial, Metastases: A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours (clinicaltrials.gov) - Jun 3, 2021
P1, N=33, Not yet recruiting, Sponsor: RemeGen Co., Ltd.